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Background: The ABSORB Cohort A trial results demonstrated the safety of
Absorb BRS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients with single
de novo native coronary artery lesions, with a low long-term MACE rate at 5
years (3.4%) and no scaffold thrombosis. Non-invasive MSCT imaging at 5
years conﬁrmed the patency of the vessels with a non-signiﬁcant decrease in
plaque area. The ABSORB Cohort B trial, a continuation of that assessment with
a modiﬁed Absorb BRS, enrolled 101 patients at 12 sites in Europe and Asia
Paciﬁc.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups,
Cohort B1 (45 patients) having imaging follow-up performed at 180 days, 2 years and
5 years and Cohort B2 (56 patients) having imaging follow-up performed at 1, 3 years
and 5 years.Five-year data for Cohort B1 are currently being collected.
Results: In the ABSORB Cohort B trial, the mean age was 62 years. Patients with
diabetes: 17%, hypertension: 66%, hypercholesterolemia: 85%, family history of
CAD: 55%, stable angina: 68%, of which 15% having stable angina with CCS
classiﬁcation of III or IV. Patients with unstable angina: 15%, 2% with unstable
angina of Braunwald Class III. Lesion location was RCA (33%), LAD (43%), LCX
(22%) and Ramus (1%), with ACC/AHA lesion classiﬁcation of B1 for 55%, B2
for 40% and C for 4%. In Group B2, late loss at 3 years was 0.29  0.43mm,
unchanged from 1 year (0.27 0.34mm) and vasomotion, as a response to nitro-
glycerine injection, was demonstrated. Quantitative IVUS results revealed mean
scaffold area and mean lumen area enlargement between baseline and 3 years. The
scaffold enlargement at 3 years was conﬁrmed by OCT. At 3 years, the strut cores
were still visible on OCT, which is in line with earlier pre-clinical data showing
that the scaffold is biodegraded and replaced by provisional matrix at 3 years.
Hypothetically, due to the integration process after bioresorption, further lumen
enlargement as well as wall thinning could be expected at later time points.
Clinical data up to 4 years showed an ID-MACE rate of 10.1% with no events of
scaffold thrombosis.
Conclusions: The long-term 5-year QCA and vasomotion results for Cohort B1 will
be presented.TCT-620
Twelve-Month Clinical Results After Bioresorbable Scaffolds – The ASSURE
Registry
Christoph Naber1, Jochen Wöhrle2, Thomas Schmitz3, Carsten Schwencke4,
Norbert Frey5, Christian Butter6, Johannes Brachmann7, Maja Ingwersen8,
Anna Drabik9, Sinisa Marcovic10, Detlef Mathey4
1Contilia Heart and Vascular Centre, Elisabeth Krankenhaus Essen, Germany, Essen,
Germany, 2University Hospital Ulm, Ulm, Germany, 3Contilia Heart and VascularJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteCenter Essen, Essen, Germany, 4University Cardiovascular Center Hamburg,
Hamburg, Germany, 5University Medical Center Schleswig-Holstein, Campus Kiel,
Kiel, Germany, 6Herzzentrum Brandenburg, Bernau, Germany, 7Klinikum Coburg,
Coburg, Germany, 8University Cardiovascular Center Hamburg, Germany,
Hamburg, Germany, 9University Medical Center Hamburg-Eppendorf, Hamburg,
Germany, 10University of Ulm, Ulm, Germany
Background: Previous ABSORB studies proved safety and efﬁcacy of bioresorbable
vascular scaffolds (BVS, Abbott Vascular Inc., Santa Clara, CA) under clinical study
conditions. However, in a real world setting including patients with a worse health
status, a higher proportion of complex lesions and waiving obligatory IVUS or OCT
guidance, BVS treatment has not been evaluated. For this purpose, we set up the
ASSURE registry over a period of 3 years.
Methods: Unselected, consecutive patients with de novo native coronary artery dis-
ease were enrolled at 6 German centers in the prospective, observational registry.
Outcomes were procedural success and occurrence of cardiovascular death, myocar-
dial infarction, ischemia driven target lesion revascularization, and target vessel failure
or revascularization. Angiographic parameters including independent quantitative
coronary angiography were assessed pre and post procedure. One-year experience is
being reported.
Results: A total of 183 patients (198 lesions) were treated with BVS. In 128
(64.7%) lesions a complex ACC/AHA morphology (B2 or C) was present. Proce-
dural success was achieved in all patients. Acute gain of minimal lumen diameter
was 1.54  0.51 mm. Through 12 months, 1 patient (0,5%) died from gastroin-
testinal bleeding, 3 (1.7%) non-target vessel myocardial infarctions occurred, and 5
(2.8%) target lesion revascularizations (TLR) had become necessary because of in-
scaffold restenosis. No scaffold thrombosis occurred. The 12-month MACE inci-
dence of 5.0% was in the same range as in previous BVS studies (4.2% in ABSORB
Cohort B; 6.9% in ABSORB EXTEND preliminary data from 450 patients) and in
everolimus eluting metallic stent trials (4.1% in SPIRIT IV). At 12 months, angina
pectoris was less frequent (17.3% versus 56.8%), as was unstable angina pectoris
(1.7% versus 21.3%).
Conclusions: One-year ASSURE results suggest that BVS for de novo coronary ar-
tery disease are associated with favorable clinical and functional outcomes in all day
clinical practice without mandatory IVUS or OCT guidance (ClinicalTrials.gov:
NCT01583608).TCT-621
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Background: There is limited outcome data on the use of the ABSORB bioresorbable
vascular scaffold (BVS) in daily clinical practice, in particular in acute coronary
syndrome (ACS) patients and more complex lesions. The aim of this study was to
evaluate the clinical outcome after BVS implantation in both simple and complex
lesions in stable patients and acute coronary syndrome patients, similar to a more “real
world” population.
Methods: All patients assigned to treatment with BVS between August 2012 and
August 2013 were included in this single center registry. 12-month clinical outcomes
assessed were cardiac death, myocardial infarction (MI), stent thrombosis (ST), target
lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel
failure (TVF). TVF was deﬁned as a composite of the device oriented endpoints of all-
cause mortality, any MI or TVR.
Results: A total of 135 patients (59  11 years, 73% male, 20% diabetic) were
enrolled and 159 lesions were treated. Stable angina was the indication for PCI in
47%, and ST-segment elevation myocardial infarction (STEMI) in 13%. The majority
of the lesions (67%) were lesion type B2 or C (AHA/ACC classiﬁcation), including 2
left main, 13 chronic total occlusions and 24 bifurcation lesions. Median follow-up
duration was 378 days [Q1-Q3: 201-435]. At twelve months the individual clinical
endpoint of cardiac death occurred in one patient (12-month cumulative event rate
0.8%), MI in 5 (4.3%), TLR in 11 (9.8%) and TVR in 14 (12.0%). ST occurred in 4
patients (12-month cumulative deﬁnite ST rate of 3.0%). All cases of ST were
angiographic deﬁned as deﬁnite, including three sub-acute and one late-ST. In sum-
mary, the composite endpoint of TVF occurred in 15 patients resulting in a 12-month
cumulative event rate of 13.2%.
Conclusions: Based on the results of the current study we believe that implantation of
the ABSORB BVS in a “real world” patient population is applicable and associated
with acceptable clinical outcomes at twelve months. Complete 12-month follow-up
results will be available at TCT 2014.nts - Drug-eluting: Bioresorbable Scaffolds B181
